FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893380085> ?p ?o ?g. }

• W2893380085 endingPage "248" @default.
• W2893380085 startingPage "242" @default.
• W2893380085 abstract "BACKGROUND Considering the importance of Helicobacter pylori (H. pylori) eradication, this clinical trial was designed to prospectively evaluate the efficacy of levofloxacin-based, sequential therapy in comparison with quadruple therapy for eradicating H. pylori. METHODS Overall 156 patients with dyspepsia and H. pylori infection were included in this study and were randomly allocated to either 10-day sequential therapy group (group A) to receive pantoprazole (40 mg twice daily), amoxicillin (1 gr twice daily), levofloxacin (500 mg twice daily), and tinidazole (500 mg twice daily) (PALT) or 14-day quadruple therapy group (group B) to receive pantoprazole, clarithromycin, bismuth subcitrate, and amoxicillin (PABC). At the end of the study the eradication rate in each group was assessed by urea breath test (UBT). RESULTS Age range of the participants was 18-65 years (average 36.9 years) and 50% of them (78 patients) were men. 78 patients were allocated to group A and 78 patients to groupe B. After antibiotic therapy, all the patients received acid suppression therapy with Proton Pump Inhibitor (PPI) for 4 weeks and then the eradication rate was confirmed by UBT (Heli FAN plus 13C, Germany). Before performing UBT, all the participants were requested to halt consumption of PPI for at least 1 week. During the treatment there was not any major complication but in group A (sequential therapy), two patients complained of minor complications including musculoskeletal pain. None of the patients in group B had any complaint or side effect. The rate of H. pylori eradication in group A was 78.2% (61 patients) while this rate in group B was 83.3% (65 patients) with no significant difference between the two groups (p = 0.42). In subgroup analysis, the rate of eradication among men in group A and B were 76.9% and 89.7%, respectively (p = 0.22) while the eradication rate among women were 79.4% and 76.9%, respectively (p = 1.00). CONCLUSION It seems that levofloxacin base sequential therapy does not have any advantage in comparison with quadruple regimen and until finding any more effective short course therapy for H. Pylori eradication; we encourage quadruple regimen to be used as the first line therapy." @default.
• W2893380085 created "2018-10-05" @default.
• W2893380085 creator A5004349885 @default.
• W2893380085 creator A5020700794 @default.
• W2893380085 creator A5030830005 @default.
• W2893380085 creator A5085278966 @default.
• W2893380085 creator A5088876410 @default.
• W2893380085 date "2018-09-06" @default.
• W2893380085 modified "2023-09-28" @default.
• W2893380085 title "Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial" @default.
• W2893380085 cites W101966804 @default.
• W2893380085 cites W1797829304 @default.
• W2893380085 cites W1818442453 @default.
• W2893380085 cites W1928203757 @default.
• W2893380085 cites W1969582334 @default.
• W2893380085 cites W1972377088 @default.
• W2893380085 cites W1973089478 @default.
• W2893380085 cites W1977272430 @default.
• W2893380085 cites W1981058900 @default.
• W2893380085 cites W1982183146 @default.
• W2893380085 cites W1994875051 @default.
• W2893380085 cites W2000422965 @default.
• W2893380085 cites W2002335744 @default.
• W2893380085 cites W2005403936 @default.
• W2893380085 cites W2012160272 @default.
• W2893380085 cites W2013134902 @default.
• W2893380085 cites W2042045508 @default.
• W2893380085 cites W2072179143 @default.
• W2893380085 cites W2080839245 @default.
• W2893380085 cites W2088365706 @default.
• W2893380085 cites W2099161366 @default.
• W2893380085 cites W2114416373 @default.
• W2893380085 cites W2125173799 @default.
• W2893380085 cites W2125329981 @default.
• W2893380085 cites W2133281678 @default.
• W2893380085 cites W2153165213 @default.
• W2893380085 cites W2154994164 @default.
• W2893380085 cites W2158819521 @default.
• W2893380085 cites W2168705005 @default.
• W2893380085 cites W2172178933 @default.
• W2893380085 cites W2181371071 @default.
• W2893380085 cites W2223526590 @default.
• W2893380085 cites W2290736004 @default.
• W2893380085 cites W2312403996 @default.
• W2893380085 cites W2318091911 @default.
• W2893380085 cites W2369554056 @default.
• W2893380085 cites W2379074562 @default.
• W2893380085 cites W2413376451 @default.
• W2893380085 cites W2417559653 @default.
• W2893380085 cites W2418075026 @default.
• W2893380085 cites W2471173873 @default.
• W2893380085 cites W2474161439 @default.
• W2893380085 cites W2551152331 @default.
• W2893380085 cites W2566256999 @default.
• W2893380085 cites W2584985211 @default.
• W2893380085 cites W2589110505 @default.
• W2893380085 cites W2652744328 @default.
• W2893380085 cites W2801940354 @default.
• W2893380085 cites W2341002333 @default.
• W2893380085 doi "https://doi.org/10.15171/mejdd.2018.117" @default.
• W2893380085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6488509" @default.
• W2893380085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31049172" @default.
• W2893380085 hasPublicationYear "2018" @default.
• W2893380085 type Work @default.
• W2893380085 sameAs 2893380085 @default.
• W2893380085 citedByCount "11" @default.
• W2893380085 countsByYear W28933800852019 @default.
• W2893380085 countsByYear W28933800852020 @default.
• W2893380085 countsByYear W28933800852021 @default.
• W2893380085 countsByYear W28933800852022 @default.
• W2893380085 countsByYear W28933800852023 @default.
• W2893380085 crossrefType "journal-article" @default.
• W2893380085 hasAuthorship W2893380085A5004349885 @default.
• W2893380085 hasAuthorship W2893380085A5020700794 @default.
• W2893380085 hasAuthorship W2893380085A5030830005 @default.
• W2893380085 hasAuthorship W2893380085A5085278966 @default.
• W2893380085 hasAuthorship W2893380085A5088876410 @default.
• W2893380085 hasBestOaLocation W28933800851 @default.
• W2893380085 hasConcept C126322002 @default.
• W2893380085 hasConcept C141071460 @default.
• W2893380085 hasConcept C168563851 @default.
• W2893380085 hasConcept C202953159 @default.
• W2893380085 hasConcept C2775981797 @default.
• W2893380085 hasConcept C2776409635 @default.
• W2893380085 hasConcept C2776962512 @default.
• W2893380085 hasConcept C2777172195 @default.
• W2893380085 hasConcept C2777498785 @default.
• W2893380085 hasConcept C2778715236 @default.
• W2893380085 hasConcept C2779116819 @default.
• W2893380085 hasConcept C2779708577 @default.
• W2893380085 hasConcept C2781025758 @default.
• W2893380085 hasConcept C2781276175 @default.
• W2893380085 hasConcept C2781315423 @default.
• W2893380085 hasConcept C2908868296 @default.
• W2893380085 hasConcept C501593827 @default.
• W2893380085 hasConcept C71924100 @default.
• W2893380085 hasConcept C86803240 @default.
• W2893380085 hasConcept C89423630 @default.

• next